| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
(Biotech Stocks Hitting 52-week Highs Sept. 2)
(Biotech Stocks Hitting 52-week Lows Sept. 2)
In an abstract submitted to the International Gynecologic Cancer Society annual global meeting, Sutro Biopharma Inc (NASDAQ:STRO) said STRO-002, its FRα-targeting antibody-drug conjugate being evaluated for ovarian cancer, produced a partial response in five of 29 evaluable patients (17%), with two confirmed on second scan.
STRO-002 has a promising emerging safety and efficacy profile and a preliminary clinical benefit/disease control rate of 48% in patients with relapsed/refractory ovarian cancer treated at more than or equal to 2.9 mg/kg.
No ocular toxicity signals have been observed, suggesting potential differentiation from other FRα-targeting investigational therapies, the company said.
Sutro said it has planned expansion cohorts in less heavily pre-treated patients for the fourth quarter of 2020.
Sutro said it will host a conference to discuss the updated data at 5:30 p.m. ET Sept. 9, and also make a presentation at the IGCS global meeting.
The stock advanced 10.96% to $12.50 in after-hours trading.
Fulgent Genetics Inc (NASDAQ:FLGT) said it is partnering with the New York City Health and Hospitals to provide COVID-19 testing to students across approximately 1,600 locations as they return to school in September and over the next several months.
Fulgent will provide its FDA EUA-approved at-home RT-PCR test, which it said provides the highest level of sensitivity and specificity, utilizing a self-collected nasal swab sample.
The company said it will provide results within 24-48 hours from the time when it receives and accepts a specimen for the test.
This is one of the first large-scale testing programs for COVID-19 to utilize an at-home test kit, Fulgent said.
Separately, the company said that beginning Sept. 28, all patients tested for COVID-19 by Fulgent will also receive results for influenzas A and B.
The stock was trading 12.56% higher to $32.45 premarket Thursday.
Novavax, Inc. (NASDAQ:NVAX) announced publication in The New England Journal of Medicine more detailed Phase 1 data from its Phase 1/2 clinical trial of NVX CoV2373, showing the vaccine candidate demonstrated a reassuring safety and reactogenicity profile and induced robust antibody responses that are numerically superior to those seen in human convalescent sera.
"The rapid publication of Phase 1 results from our trial in a prestigious peer-reviewed journal reflects both the importance of the data and the urgent need for an effective vaccine to slow the COVID-19 pandemic," Gregory Glenn, Novavax's R&D president, said in a statement.
The company released preliminary Phase 1 data in early August.
The stock was up 5.45% at $108.51 premarket.
Sanofi SA (NASDAQ:SNY) and GlaxoSmithKline plc (NYSE:GSK) said they have started the Phase 1/2 clinical trial of their adjuvanted COVID-19 vaccine. The vaccine candidate uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza vaccines alongside GSK's established pandemic adjuvant technology.
About 440 healthy adults from 11 sites in the U.S. are being enrolled in the trial, which is designed to evaluate safety, reactogenicity and immunogenicity.
The companies expect to release preliminary data from the study in early December, which is likely to help initiation of a Phase 3 trial in December. Contingent on the data, the companies said they plan to file a regulatory application in the first half of 2021.
ADMA Biologics Inc (NASDAQ:ADMA) announced the launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary, fully validated ELISA assay for the detection of SARS-CoV-2 neutralizing antibodies in plasma.
ImmunoRank was developed in collaboration with Leinco Technologies, and is intended for use as an aid to identify individuals who produce an adaptive immune response to SARS-CoV-2, indicating recent or prior infection, and specifically for the detection of circulating SARS-CoV-2 neutralizing antibodies in human plasma of all immune globulin classes.
The stock was moving up 12.72% to $2.57 in premarket trading Thursday.
Related Link: Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
Posted In: ACOR ADMA ADTX AFIB AKUS BLFS CDMO COO CORT CYCC ENTX EVGN EW EYPT FBIO FLGT GBIO GRTS GSK HAPP
